Leukemia

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

EA9161 Addition of Venetoclax to Ibrutinib and Obinutuzumab vs Ibrutinib and Obinutuzumab in Untreated Younger Patients with CLL

Study Details

  • Study Site/Tumor Location: Leukemia
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information